Contact MaRS Discovery District for event and ticket information.
Friday, September 11, 2009 from 12:00 PM - 1:30 PM (ET)
The MaRS Future of Medicine Series is an informal
moderated forum bringing together research professionals and clinicians
interested in drug development. At this session, Dr. Wayne Danter will discuss an in silico process for predicting target biological activities from molecular structure.
Speaker: Dr. Wayne Danter, Critical Outcome Technologies Inc.
Each session has a 30-minute presentation and a 45-minute moderated
discussion. For more information on this series or to register for a
specific event please contact MaRS at events@marsdd.com.
Generously supported by:
ABOUT THE SPEAKER
Dr. Wayne Danter
Dr. Danter is the President, Chief Scientific Officer, and a Director of Critical Outcome Technologies Inc (COTI). He is the inventor of the CHEMSAS® process and one of the founders of COTI. He trained at the University of Western Ontario in Internal Medicine and Clinical Pharmacology. Prior to founding COTI, Dr. Danter was an Associate Professor of Medicine at the University of Western Ontario. His clinical focus, in addition to his teaching role, at the university was in General Cardiology, Cardiovascular Diseases associated with HIV and Cardiovascular Risk Management.
Dr. Danter's initial research focused on the medical application of Artificial Intelligence (AI) technologies to disease diagnosis and outcome prediction. The primary aspect of his research has focused on developing Hybrid AI models to pattern the relationship between molecular structure and biological activity. This research has resulted in a sophisticated process for decomposing complex molecules into critical elements that permit accurate molecular structure activity modeling (CHEMSAS). His research has been published in peer-reviewed publications and he has presented at numerous international meetings. Dr. Danter is a pioneer in the evolving interface between AI Technologies and pharmacotherapeutics. These AI technologies are anticipated to play a major role in 21st century drug development.
MaRS (www.marsdd.com) is a non-profit organization focused on maximizing the economic and social impact of Canadian innovation. MaRS was founded in 2000 by leaders from the private and public sectors in order to improve commercial outcomes from Canada’s strong foundation of science and technology innovation. MaRS connects and fosters collaboration between the communities of science, business and capital through co-location in the MaRS Centre and more broadly through catalytic programs, structured networks and the MaRS web portal. The MaRS Centre opened in 2005.
 |
View other MaRS Discovery District events |
 |
Contact the Host |
 |
Subscribe to receive notifications of future events by this host |
Email
Facebook
Twitter
LinkedIn
MySpace
Digg
del.icio.us
Reddit